OncoMatch/Non-Hodgkin Lymphoma (NHL)/MYC rearrangement
Non-Hodgkin Lymphoma (NHL)MYC rearrangement Clinical Trials
MYC rearrangements define Burkitt lymphoma (near-universally) and high-grade B-cell lymphoma (double/triple-hit with BCL2/BCL6) among NHL subtypes, and confer aggressive biology and poor outcomes with standard regimens. Intensive regimens (R-CODOX-M/IVAC, DA-EPOCH-R) are used in MYC-rearranged aggressive NHL. Trials investigate first-line CAR-T therapy, polatuzumab vedotin combinations, and novel MYC-directed approaches for this unmet-need population.
Top recruiting MYC rearrangement Non-Hodgkin Lymphoma (NHL) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
More MYC rearrangement Non-Hodgkin Lymphoma (NHL) trials
9 international trials (no US sites)
Browse other molecular targets with active Non-Hodgkin Lymphoma (NHL) trials.